Indications
Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?-glucosidase deficiency).
Composition
- Active substance
- avalglucosidase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nexviadyme
- Active substance
- avalglucosidase alfa
- ATC code
- A16
- Therapeutic area
- Glycogen Storage Disease Type II
- Marketing authorisation holder
- Sanofi B.V.
- Status
- Authorised
- EU authorisation